Skip to main content
. Author manuscript; available in PMC: 2021 Jun 8.
Published in final edited form as: Cell Rep. 2020 Dec 8;33(10):108474. doi: 10.1016/j.celrep.2020.108474

Figure 7. BAZ2B-induced multipotent hematopoietic progenitors possess long-term engraftment potential.

Figure 7.

(A) Lin-CD34+CD38+ committed progenitors were sorted and transduced with Luciferase or BAZ2B followed by NSG mice transplantation (See STAR Methods, for details). Human hematopoietic engraftment was analyzed after 16 weeks. (B) FACS plot showing engraftment of human CD45+ hematopoietic cells in the mouse bone marrow upon expression of BAZ2B or Luciferase in Lin-CD34+CD38+ committed progenitors. Percentage fractions for hCD45 gate normalized to live cells represented as mean ± SD. CD33+ myeloid and CD19+ lymphoid gates show the lineage potential for the human CD45+ cells. Percentage fractions for hCD33/hCD19 gate normalized to hCD45+ cells represented as mean ± SD. N = 3 donors with 2-3 mice per donor. (C) Quantification of the engraftment of human CD45+ cells with respect to total live cells in the bone marrow, spleen and peripheral blood. Two-tailed unpaired t-test. (D) Quantification of the CD33+ myeloid and CD19+ lymphoid cells with respect to the total human CD45+ hematopoietic cells from Luciferase or BAZ2B-induced multipotent hematopoietic progenitors.